Salman Jasim M, Hadi Huda M
Anesthesiology and Critical Care, University of Basrah, College of Medicine, Basrah, IRQ.
Anesthesiology, Basrah Health Directorate, Basrah, IRQ.
Cureus. 2025 Jun 29;17(6):e87010. doi: 10.7759/cureus.87010. eCollection 2025 Jun.
Neostigmine, a reversible acetylcholinesterase inhibitor (AChEI), has shown potential as an adjunct to local anesthetics like lidocaine in peripheral nerve blocks, including carpal tunnel syndrome (CTS). It may prolong analgesia by activating muscarinic receptors involved in pain modulation. Some studies report that adding neostigmine to lidocaine improves the duration of anesthesia and postoperative pain relief, particularly in upper limb procedures. However, results are mixed, possibly due to differences in doses or nerve barrier permeability. Overall, neostigmine's role in enhancing analgesia in nerve blocks such as Bier's block and CTS remains an active area of investigation.
This study aims to assess the analgesic efficacy of adding 0.5 mg neostigmine to 2% lidocaine in adult patients undergoing upper limb surgery under intravenous regional anesthesia (IVRA). Specifically, it evaluates the impact of this combination on intraoperative and postoperative pain, analgesic requirements, and recovery profiles, thereby contributing to improved perioperative pain management strategies.
A total of 52 patients admitted to Al-Fayhaa Teaching Hospital, Basrah, Iraq, were randomized into two groups of 26 patients each. One patient excluded from analysis from each group. In the control group, local anesthesia of 3 mg/kg lidocaine was administered with 40 mL of normal saline. While the neostigmine group patients received 3 mg/kg lidocaine with 0.5 mg neostigmine, the same amount of saline was administered. Physiological parameters, sensation, and motor activity onset time, and recovery time after intravenous regional anesthesia were registered.
The neostigmine group included males (4%) and females (96%) with a mean age of 41.76±5.69 years, while the control group included males (20%) and females (80%) with a mean age of 37.6±5.00 years. There were no differences in the demographic data (American Society of Anesthesiologists (ASA), gender, weight), in addition to pinprick onset and recovery times, touch onset time, and block recovery time between both groups. A significant difference was observed in the age, surgical duration time, tourniquet time, touch recovery time, and motor block onset time between both groups (p < 0.05). In addition, no significant differences in postoperative complications were observed between the two groups (p = 0.074). However, there was a significant association in analgesic need, whether intraoperative or to reduce tourniquet pain, among the compared groups (p < 0.001).
The addition of neostigmine to lidocaine in the surgical treatment of CTS shows no significant benefits regarding postoperative pain relief, but it is of benefit during the operation.
新斯的明是一种可逆性乙酰胆碱酯酶抑制剂(AChEI),已显示出在包括腕管综合征(CTS)在内的周围神经阻滞中作为利多卡因等局部麻醉剂辅助药物的潜力。它可能通过激活参与疼痛调节的毒蕈碱受体来延长镇痛时间。一些研究报告称,在利多卡因中添加新斯的明可改善麻醉持续时间和术后疼痛缓解,尤其是在上肢手术中。然而,结果不一,可能是由于剂量或神经屏障通透性的差异。总体而言,新斯的明在增强如 Bier 阻滞和 CTS 等神经阻滞镇痛方面的作用仍是一个活跃的研究领域。
本研究旨在评估在接受静脉区域麻醉(IVRA)的上肢手术成年患者中,在 2%利多卡因中添加 0.5 毫克新斯的明的镇痛效果。具体而言,它评估了这种组合对术中及术后疼痛、镇痛需求和恢复情况的影响,从而有助于改进围手术期疼痛管理策略。
伊拉克巴士拉法哈教学医院共收治 52 例患者,随机分为两组,每组 26 例。每组各有 1 例患者被排除分析。对照组给予 3 毫克/千克利多卡因加 40 毫升生理盐水进行局部麻醉。新斯的明组患者接受 3 毫克/千克利多卡因加 0.5 毫克新斯的明,并给予相同量的生理盐水。记录静脉区域麻醉后的生理参数、感觉和运动活动起效时间以及恢复时间。
新斯的明组包括男性(4%)和女性(96%),平均年龄为 41.76±5.69 岁,而对照组包括男性(20%)和女性(80%),平均年龄为 37.6±5.00 岁。两组在人口统计学数据(美国麻醉医师协会(ASA)分级、性别、体重)以及针刺起效和恢复时间、触觉起效时间和阻滞恢复时间方面均无差异。两组在年龄、手术持续时间、止血带时间、触觉恢复时间和运动阻滞起效时间方面存在显著差异(p < 0.05)。此外,两组术后并发症无显著差异(p = 0.074)。然而,在比较组中,无论是术中还是减轻止血带疼痛的镇痛需求方面存在显著关联(p < 0.001)。
在 CTS 手术治疗中,在利多卡因中添加新斯的明在术后疼痛缓解方面未显示出显著益处,但在手术过程中有益。